Cannabidiol induces systemic analgesia through activation of the PI3Kγ/nNOS/NO/KATP signaling pathway in neuropathic mice. A KATP channel S-nitrosylation-dependent mechanism.

Analgesia Cannabidiol Neuropathic pain Nitric oxide S-Nitrosylation

Journal

Nitric oxide : biology and chemistry
ISSN: 1089-8611
Titre abrégé: Nitric Oxide
Pays: United States
ID NLM: 9709307

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 06 11 2023
revised: 26 02 2024
accepted: 27 02 2024
medline: 2 3 2024
pubmed: 2 3 2024
entrez: 1 3 2024
Statut: aheadofprint

Résumé

Cannabidiol (CBD) is the second most abundant pharmacologically active component present in Cannabis sp. Unlike Δ-9-tetrahydrocannabinol (THC), it has no psychotomimetic effects and has recently received significant interest from the scientific community due to its potential to treat anxiety and epilepsy. CBD has excellent anti-inflammatory potential and can be used to treat some types of inflammatory and neuropathic pain. In this context, the present study aimed to evaluate the analgesic mechanism of cannabidiol administered systemically for the treatment of neuropathic pain and determine the endogenous mechanisms involved with this analgesia. Neuropathic pain was induced by sciatic nerve constriction surgery, and the nociceptive threshold was measured using the paw compression test in mice. CBD produced dose-dependent antinociception after intraperitoneal injection. Selective inhibition of PI3Kγ dose-dependently reversed CBD-induced antinociception. Selective inhibition of nNOS enzymes reversed the antinociception induced by CBD, while selective inhibition of iNOS and eNOS did not alter this antinociception. However, the inhibition of cGMP production by guanylyl cyclase did not alter CBD-mediated antinociception, but selective blockade of ATP-sensitive K+ channels dose-dependently reversed CBD-induced antinociception. Inhibition of S-nitrosylation dose-dependently and completely reversed CBD-mediated antinociception. Cannabidiol has an antinociceptive effect when administered systemically and this effect is mediated by the activation of PI3Kγ as well as by nitric oxide and subsequent direct S-nitrosylation of K

Sections du résumé

BACKGROUND BACKGROUND
Cannabidiol (CBD) is the second most abundant pharmacologically active component present in Cannabis sp. Unlike Δ-9-tetrahydrocannabinol (THC), it has no psychotomimetic effects and has recently received significant interest from the scientific community due to its potential to treat anxiety and epilepsy. CBD has excellent anti-inflammatory potential and can be used to treat some types of inflammatory and neuropathic pain. In this context, the present study aimed to evaluate the analgesic mechanism of cannabidiol administered systemically for the treatment of neuropathic pain and determine the endogenous mechanisms involved with this analgesia.
METHODS METHODS
Neuropathic pain was induced by sciatic nerve constriction surgery, and the nociceptive threshold was measured using the paw compression test in mice.
RESULTS RESULTS
CBD produced dose-dependent antinociception after intraperitoneal injection. Selective inhibition of PI3Kγ dose-dependently reversed CBD-induced antinociception. Selective inhibition of nNOS enzymes reversed the antinociception induced by CBD, while selective inhibition of iNOS and eNOS did not alter this antinociception. However, the inhibition of cGMP production by guanylyl cyclase did not alter CBD-mediated antinociception, but selective blockade of ATP-sensitive K+ channels dose-dependently reversed CBD-induced antinociception. Inhibition of S-nitrosylation dose-dependently and completely reversed CBD-mediated antinociception.
CONCLUSION CONCLUSIONS
Cannabidiol has an antinociceptive effect when administered systemically and this effect is mediated by the activation of PI3Kγ as well as by nitric oxide and subsequent direct S-nitrosylation of K

Identifiants

pubmed: 38428514
pii: S1089-8603(24)00028-4
doi: 10.1016/j.niox.2024.02.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Douglas Lamounier de Almeida (DL)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Renata Cristina Mendes Ferreira (RC)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Flávia Cristina Fonseca (FC)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Daniel Portela Dias Machado (DP)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Danielle Diniz Aguiar (DD)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Francisco Silveira Guimaraes (FS)

Department of Pharmacology, FMRP, Campus USP, University of São Paulo, Av. Bandeirantes 13400, Ribeirão Preto, SP, 14049-900, Brazil.

Igor Dimitri Gama Duarte (IDG)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil.

Thiago Roberto Lima Romero (TRL)

Laboratory of Pain and Analgesia, Pharmacology Department, ICB/UFMG, Brazil. Electronic address: thiromero@gmail.com.

Classifications MeSH